137 related articles for article (PubMed ID: 38868944)
21. [Efficacy of alcohol septal ablation in mildly symptomatic or severely symptomatic patients with hypertrophic obstructive cardiomyopathy].
Sun JJ; Li PJ; Yu XP; Zhao H; Zhang XL; Tu CC; Zhang MD; Jiang TY; Song XT; He JQ
Zhonghua Xin Xue Guan Bing Za Zhi; 2023 May; 51(5):513-520. PubMed ID: 37198123
[No Abstract] [Full Text] [Related]
22. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
23. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE
Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706
[TBL] [Abstract][Full Text] [Related]
24. Prognostic relevance of exercise testing in hypertrophic cardiomyopathy. A systematic review.
Rodrigues T; Raposo SC; Brito D; Lopes LR
Int J Cardiol; 2021 Sep; 339():83-92. PubMed ID: 34214502
[TBL] [Abstract][Full Text] [Related]
25. Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design.
Coats CJ; Maron MS; Abraham TP; Olivotto I; Lee MMY; Arad M; Cardim N; Ma CS; Choudhury L; Düngen HD; Garcia-Pavia P; Hagège AA; Lewis GD; Michels M; Oreziak A; Owens AT; Tfelt-Hansen J; Veselka J; Watkins HC; Heitner SB; Jacoby DL; Kupfer S; Malik FI; Meng L; Wohltman A; Masri A;
JACC Heart Fail; 2024 Jan; 12(1):199-215. PubMed ID: 38032573
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of atrial fibrillation in hypertrophic cardiomyopathy: a systematic review.
Alphonse P; Virk S; Collins J; Campbell T; Thomas SP; Semsarian C; Kumar S
Clin Res Cardiol; 2021 Apr; 110(4):544-554. PubMed ID: 32880676
[TBL] [Abstract][Full Text] [Related]
27. Decline in peak oxygen consumption over time predicts death or transplantation in adults with a Fontan circulation.
Cunningham JW; Nathan AS; Rhodes J; Shafer K; Landzberg MJ; Opotowsky AR
Am Heart J; 2017 Jul; 189():184-192. PubMed ID: 28625375
[TBL] [Abstract][Full Text] [Related]
28. Cardiopulmonary exercise test in patients with obstructive hypertrophic cardiomyopathy.
Cui H; Schaff HV; Olson TP; Geske JB; Dearani JA; Nishimura RA; Sun D; Ommen SR
J Thorac Cardiovasc Surg; 2024 Feb; 167(2):701-710.e3. PubMed ID: 35798610
[TBL] [Abstract][Full Text] [Related]
29. Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes.
Sharma S; Elliott PM; Whyte G; Mahon N; Virdee MS; Mist B; McKenna WJ
J Am Coll Cardiol; 2000 Sep; 36(3):864-70. PubMed ID: 10987612
[TBL] [Abstract][Full Text] [Related]
30. Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Wheeler MT; Jacoby D; Elliott PM; Saberi S; Hegde SM; Lakdawala NK; Myers J; Sehnert AJ; Edelberg JM; Li W; Olivotto I
Eur J Heart Fail; 2023 Feb; 25(2):260-270. PubMed ID: 36404399
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Demographic, Clinical, Biochemical, and Imaging Findings in Hypertrophic Cardiomyopathy Prognosis: A Network Meta-Analysis.
Georgiopoulos G; Figliozzi S; Pateras K; Nicoli F; Bampatsias D; Beltrami M; Finocchiaro G; Chiribiri A; Masci PG; Olivotto I
JACC Heart Fail; 2023 Jan; 11(1):30-41. PubMed ID: 36599547
[TBL] [Abstract][Full Text] [Related]
32. [Predicting value of 2014 European guidelines risk prediction model for sudden cardiac death (HCM Risk-SCD) in Chinese patients with hypertrophic cardiomyopathy].
Li WX; Liu LW; Wang J; Zuo L; Yang F; Kang N; Lei CH
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Dec; 45(12):1033-1038. PubMed ID: 29325362
[No Abstract] [Full Text] [Related]
33. The Prevalence and Association of Exercise Test Abnormalities With Sudden Cardiac Death and Transplant-Free Survival in Childhood Hypertrophic Cardiomyopathy.
Conway J; Min S; Villa C; Weintraub RG; Nakano S; Godown J; Tatangelo M; Armstrong K; Richmond M; Kaufman B; Lal AK; Balaji S; Power A; Baez Hernandez N; Gardin L; Kantor PF; Parent JJ; Aziz PF; Jefferies JL; Dragulescu A; Jeewa A; Benson L; Russell MW; Whitehill R; Rossano J; Howard T; Mital S
Circulation; 2023 Feb; 147(9):718-727. PubMed ID: 36335467
[TBL] [Abstract][Full Text] [Related]
34. Cardiopulmonary Exercise Testing in Athletes With Hypertrophic Cardiomyopathy.
Newman DB; Garmany R; Contreras AM; Bos JM; Johnson JN; Geske JB; Allison TG; Ommen SR; Ackerman MJ
Am J Cardiol; 2023 Feb; 189():49-55. PubMed ID: 36508762
[TBL] [Abstract][Full Text] [Related]
35. Catecholamine response to exercise in patients with non-obstructive hypertrophic cardiomyopathy.
Shah AB; Bechis MZ; Brown M; Finch JM; Loomer G; Groezinger E; Weiner RB; Wasfy MM; Picard MH; Fifer MA; Lewis GB; Baggish AL
J Physiol; 2019 Mar; 597(5):1337-1346. PubMed ID: 30552684
[TBL] [Abstract][Full Text] [Related]
36. Value of exercise testing in assessing clinical state and prognosis in hypertrophic cardiomyopathy.
Sharma S; Firoozi S; McKenna WJ
Cardiol Rev; 2001; 9(2):70-6. PubMed ID: 11209145
[TBL] [Abstract][Full Text] [Related]
37. Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Nassif M; Fine JT; Dolan C; Reaney M; Addepalli P; Allen VD; Sehnert AJ; Gosch K; Spertus JA
JACC Heart Fail; 2022 Aug; 10(8):531-539. PubMed ID: 35902155
[TBL] [Abstract][Full Text] [Related]
38. Estimating the prevalence, clinical characteristics, and treatment patterns of hypertrophic cardiomyopathy in Japan: A nationwide medical claims database study.
Terasaka N; Spanopoulos D; Miyagoshi H; Kubo T; Kitaoka H
J Cardiol; 2023 Mar; 81(3):316-322. PubMed ID: 36208832
[TBL] [Abstract][Full Text] [Related]
39. Safety and Utility of Cardiopulmonary Exercise Testing in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia.
Scheel PJ; Florido R; Hsu S; Murray B; Tichnell C; James CA; Agafonova J; Tandri H; Judge DP; Russell SD; Tedford RJ; Calkins H; Gilotra NA
J Am Heart Assoc; 2020 Feb; 9(3):e013695. PubMed ID: 32009524
[TBL] [Abstract][Full Text] [Related]
40. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.
Leaviss J; Davis S; Ren S; Hamilton J; Scope A; Booth A; Sutton A; Parry G; Buszewicz M; Moss-Morris R; White P
Health Technol Assess; 2020 Sep; 24(46):1-490. PubMed ID: 32975190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
